CoChat

Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer’s disease

Open access
Zou, Dajiang, Liu, Renzheng, Lv, Yangjing, Guo, Jianan, Zhang, Changjun, Xie, Yuanyuan · 2023 · Journal of Enzyme Inhibition and Medicinal Chemistry

The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.

Abstract

Alzheimer's disease (AD) is a progressive brain disease characterised by progressive memory loss and cognition impairment, ultimately leading to death. There are three FDA-approved acetylcholinesterase inhibitors (donepezil, rivastigmine, and galantamine, AChEIs) for the symptomatic treatment of AD. Monoamine oxidase B (MAO-B) has been considered to contribute to pathologies of AD. Therefore, we reviewed the dual inhibitors of acetylcholinesterase (AChE) and MAO-B developed in the last five years. In this review, these dual-target inhibitors were classified into six groups according to the basic parent structure, including chalcone, coumarin, chromone, benzo-fused five-membered ring, imine and hydrazine, and other scaffolds. Their design strategies, structure-activity relationships (SARs), and molecular docking studies with AChE and MAO-B were analysed and discussed, giving valuable insights for the subsequent development of AChE and MAO-B dual inhibitors. Challenges in the development of balanced and potent AChE and MAO-B dual inhibitors were noted, and corresponding solutions were provided.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/14756366.2023.2270781

Cites

123 of 123 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. AChEIs approved by the FDA for AD therapy.
Figure 1. AChEIs approved by the FDA for AD therapy.CC BY-NC · PubMed Central
Figure 2. Three rational design strategies to generate multifunctional molecules.
Figure 2. Three rational design strategies to generate multifunctional molecules.CC BY-NC · PubMed Central
Figure 3. Structures of promising MTDLs.
Figure 3. Structures of promising MTDLs.CC BY-NC · PubMed Central
Figure 4. Structures of natural and synthesised chalcone.
Figure 4. Structures of natural and synthesised chalcone.CC BY-NC · PubMed Central
Figure 5. Structures of compound 1-based derivatives.
Figure 5. Structures of compound 1-based derivatives.CC BY-NC · PubMed Central
Figure 6. Structures of chalcone and donepezil-based dual inhibitors.
Figure 6. Structures of chalcone and donepezil-based dual inhibitors.CC BY-NC · PubMed Central
Figure 7. Structures of other chalcone-based dual inhibitors.
Figure 7. Structures of other chalcone-based dual inhibitors.CC BY-NC · PubMed Central
Figure 8. SAR of chalcone-based dual inhibitors targeting AChE and MAO-B.
Figure 8. SAR of chalcone-based dual inhibitors targeting AChE and MAO-B.CC BY-NC · PubMed Central
Figure 9. Structures of coumarin-based inhibitors.
Figure 9. Structures of coumarin-based inhibitors.CC BY-NC · PubMed Central
Figure 10. SAR of coumarin-based dual inhibitors targeting AChE and MAO-B.
Figure 10. SAR of coumarin-based dual inhibitors targeting AChE and MAO-B.CC BY-NC · PubMed Central
Figure 11. Structures of chromone-based inhibitors.
Figure 11. Structures of chromone-based inhibitors.CC BY-NC · PubMed Central
Figure 12. SAR of chromone-based dual inhibitors targeting AChE and MAO-B.
Figure 12. SAR of chromone-based dual inhibitors targeting AChE and MAO-B.CC BY-NC · PubMed Central
Figure 13. Structures of benzo five-membered ring-based inhibitors.
Figure 13. Structures of benzo five-membered ring-based inhibitors.CC BY-NC · PubMed Central
Figure 14. Structures of imine and hydrazone-based inhibitors.
Figure 14. Structures of imine and hydrazone-based inhibitors.CC BY-NC · PubMed Central
Figure 15. Structures of other scaffold-based inhibitors.
Figure 15. Structures of other scaffold-based inhibitors.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 123 references

Cited by

See all 60

Metadata

Authors
Zou, D., Liu, R., Lv, Y., Guo, J., Zhang, C., & Xie, Y.
Affiliations
  • College of Pharmaceutical Science, Zhejiang University of Technology
  • Zhejiang University of Technology (CN)
Corresponding author
  • Zhang, Changjun
  • Xie, Yuanyuan
Venue
Journal of Enzyme Inhibition and Medicinal Chemistry
Published
2023-11-13
Volume
38
Issue
1
Pages
2270781-2270781
ISSN
  • 1475-6366 (ISSN-L)
  • 1475-6374
OpenAlex
W4388638581
Cited by
60
References
122
Citations by year
2026: 22 · 2025: 26 · 2024: 12
FWCI
2.18
Type
journal article
Language
en
Open access
Locations
  • Journal of Enzyme Inhibition and Medicinal Chemistry (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Zhejiang Key R&D Program (No. 2021C03085)
  • National Key R&D Program of China (2021YFC2100800)
  • National Natural Science Foundation of China (Grant No. 21978273 and 21576239)
  • China Postdoctoral Science Foundation (No. 2021M702897)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
Keywords
Alzheimer's disease, acetylcholinesterase inhibitors, monoamine oxidase B inhibitors, dual inhibitors, chalcones, coumarins, chromones, imines, hydrazine, structure-activity relationship, molecular docking, drug design
MeSH terms
Acetylcholinesterase, Alzheimer Disease, Cholinesterase Inhibitors, Humans, Monoamine Oxidase, Monoamine Oxidase Inhibitors, Structure-Activity Relationship, Molecular Docking Simulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer’s disease. https://app.cochat.ai/papers/10.1080/14756366.2023.2270781
The paper
Zou, D., Liu, R., Lv, Y., Guo, J., Zhang, C., & Xie, Y. (2023). Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer’s disease. Journal of Enzyme Inhibition and Medicinal Chemistry. https://doi.org/10.1080/14756366.2023.2270781

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.